Please login to the form below

Not currently logged in
Email:
Password:

FDA grants priority review to MS drug

Novartis has announced that its MS treatment, Gilenia (fingolimod) has been granted priority review status by the US FDA

Novartis has announced that its multiple sclerosis (MS) treatment, Gilenia (fingolimod) has been granted priority review status by the US Food and Drug Administration (FDA). This follows the acceptance of Novartis' regulatory submission made to the FDA in December 2009.

Gilenia is a once-daily oral therapy. Should the drug receive approval from the FDA, it has the potential to become the first approved oral therapy for the treatment of MS.

A priority review is granted by the FDA for investigational medicines that could offer significant advances beyond current treatments or where no adequate therapy exists. As a result of this designation, the standard 10-month FDA review period will be reduced to six months.

It is expected that the FDA will require an Advisory Committee meeting as Gilenia involves a new active ingredient. This could result in the FDA extending its review at the end of the six-month period in June 2010.

"We welcome the decision granting priority review to Gilenia, which underscores the potential benefits of this medicine to patients," said Dr Trevor Mundel, global head of development at Novartis Pharma AG.

"MS is a leading cause of neurological disability in young adults, particularly in women, and this medicine has the potential to offer real advances in the care of people with MS," he continued.

Data from one of the largest-ever phase III clinical trial programmes conducted in MS patients were submitted to support the US and European regulatory submissions, including results of the TRANSFORMS and FREEDOMS studies that were recently published in The New England Journal of Medicine.

Data drawn from a combination of both studies showed that Gilenia reduced relapses, disability progression and brain lesions in patients with the relapsing-remitting form of MS, which is estimated to affect around 85 per cent of MS patients.

22nd February 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Live webinar:
The power of a good story: Turn your insights into effective storytelling with data visualisation...
clinical research org
The important role of CROs in shaping the future of clinical research across Europe
Looking at the impact of COVID-19 on clinical research activities...
What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...

Infographics